<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127710</url>
  </required_header>
  <id_info>
    <org_study_id>D5082C00002</org_study_id>
    <secondary_id>GU 111</secondary_id>
    <nct_id>NCT02127710</nct_id>
  </id_info>
  <brief_title>A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)</brief_title>
  <official_title>A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate&#xD;
      the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who&#xD;
      are treatment naïve or previously treated.&#xD;
&#xD;
      An independent central pathology review of tumour samples will be used to confirm the&#xD;
      diagnosis of PRCC of all patients enrolling. However, locally available pathology results&#xD;
      confirming PRCC will be allowed for timely study entry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will comprise two stages. In Stage 1 approximately 20 patients will be enrolled.&#xD;
      This group is considered sufficient to provide preliminary assessment of the anti-tumour&#xD;
      activity of AZD6094 in the form of non-binding futility analysis.&#xD;
&#xD;
      If ≤ 2 tumour responses are observed in the first 20 evaluable patients termination of the&#xD;
      study will be considered taking into account the relevant molecular profile of the patients&#xD;
      and additional information from related studies in the drug development programme.&#xD;
&#xD;
      All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD).&#xD;
      Treatment will be given continuously.&#xD;
&#xD;
      Following the baseline assessment, efficacy will be assessed by objective tumour assessments&#xD;
      every 6 weeks (±7 days), for the first 12 months and every 12 weeks thereafter until&#xD;
      objective disease progression as defined by RECIST v1.1 There will be a data cut-off after&#xD;
      all patients have completed at least 12 weeks of treatment with AZD6094 or withdrawn. The&#xD;
      database will be locked and data analysis will be performed on this dataset.&#xD;
&#xD;
      Any patients still receiving study drug at the time of data cut-off will be able to continue&#xD;
      to receive AZD6094 while deriving clinical benefit. Such patients will continue to be&#xD;
      monitored for the occurrence of serious adverse events up to 28 days after the last dose of&#xD;
      AZD6094.&#xD;
&#xD;
      After database lock (DBL) tumour assessments will be performed every 12 weeks (±7 days) until&#xD;
      objective disease progression as defined by RECIST v1.1.&#xD;
&#xD;
      Patients discontinuing treatment due to documented disease progression will enter a survival&#xD;
      follow-up period, where they will be followed for the initiation of subsequent anti-cancer&#xD;
      therapies every 3 months until death, loss to follow-up or withdrawal of consent, whichever&#xD;
      comes first.&#xD;
&#xD;
      Patients discontinuing treatment prior to documented disease progression will enter a&#xD;
      progression-free survival follow-up period where they will continue to have disease&#xD;
      assessments every 6 weeks (±7 days) for the first 12 months of follow-up and every 12 weeks&#xD;
      thereafter until objective disease progression as defined by RECIST v1.1, death, loss to&#xD;
      follow-up or withdrawal of consent, whichever comes first. After DBL, tumour assessments will&#xD;
      be performed in the progression free survival patient population every 12 weeks (±7 days)&#xD;
      until objective disease progression as defined by RECIST v1.1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2014</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">April 14, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (RECIST Version 1.1)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to Response Evaluation Criteria for Solid Tumours (RECIST) v1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary outcome measure was ORR, defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary outcome measure was ORR, defined as the proportion of patients with either a confirmed complete response/partial response by investigator assessment according to RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Stratified by c-MET Status in the Efficacy Analysis Set</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Stratified by c-MET Status in the Efficacy Analysis Set</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Stratified by c-MET Status in the Safety Analysis Set</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Stratified by c-MET Status in the Safety Analysis Set</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Efficacy Analysis Set</measure>
    <time_frame>12 Weeks (at 12 weeks timepoint)</time_frame>
    <description>12 week summary for patients in the Efficacy analysis set, by MET status. The numbers of patients analysed represent the numbers evaluable at the 12 week timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Safety Analysis Set.</measure>
    <time_frame>12 Weeks (at 12 week timepoint)</time_frame>
    <description>12 week summary for patients in the Safety analysis set by MET Status. The number of patients analysed represent the number of evaluable patients at the 12 week timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration of Response is the time from the first documentation of confirmed complete response/partial response until the date of progression, or death in the absence of progression. There were 8 responders: one of whom subsequently progressed or died and seven of whom were still classified as responders at the time of data cut-off and were therefore censored. It was not possible to determine a median or 75th percentile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration of AZD6094 Following Single Dose</measure>
    <time_frame>24 Hours</time_frame>
    <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Plasma Concentration of AZD6094 After Single Dose</measure>
    <time_frame>24 Hours</time_frame>
    <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution of AZD6094 Following Single Dose</measure>
    <time_frame>24 Hours</time_frame>
    <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose</measure>
    <time_frame>24 Hours</time_frame>
    <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose (Time Zero to Last Measurement)</measure>
    <time_frame>24 Hours</time_frame>
    <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Clearance of AZD6094 From Plasma After Single Dose</measure>
    <time_frame>24 Hours</time_frame>
    <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time of AZD6094 After Single Dose</measure>
    <time_frame>24 Hours</time_frame>
    <description>The number of patients analysed represent the number of evaluable PK parameters for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life of AZD6094 After Single Dose</measure>
    <time_frame>24 Hours</time_frame>
    <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Papillary Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>AZD6094 600 mg daily continuously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6094</intervention_name>
    <description>AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.</description>
    <arm_group_label>AZD6094 600 mg daily continuously</arm_group_label>
    <other_name>Savolitinib</other_name>
    <other_name>HMPL - 504</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures, sampling and&#xD;
             analyses.&#xD;
&#xD;
          2. Histologically confirmed PRCC, which is locally advanced or metastatic.&#xD;
&#xD;
          3. Availability of an archival tumor sample or a pre-treatment fresh tumor sample for&#xD;
             confirmation of PRCC by a central laboratory and other biomarker&#xD;
&#xD;
          4. Treatment naïve or have failed on previous treatment for PRCC. Previous treatments may&#xD;
             include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib,&#xD;
             temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a,&#xD;
             Interleukin-2), chemotherapy or a combination of chemoimmunotherapy.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          6. At least one lesion, not previously irradiated, and not chosen for a biopsy if&#xD;
             performed during the screening period that can be accurately measured at baseline and&#xD;
             which is suitable for accurate repeated measurements.&#xD;
&#xD;
          7. Adequate hematological function defined as:&#xD;
&#xD;
               1. Absolute neutrophil count ≥1500/μL&#xD;
&#xD;
               2. Haemoglobin ≥9 g/dL&#xD;
&#xD;
               3. Platelets ≥100,000/μL&#xD;
&#xD;
          8. Adequate liver function defined as:&#xD;
&#xD;
               1. Alanine aminotransferase and aspartate aminotransferase ≤2.5 x the upper limit of&#xD;
                  normal (ULN)&#xD;
&#xD;
               2. Total bilirubin ≤1.5 x ULN&#xD;
&#xD;
          9. Adequate renal function defined as glomerular filtration rate ≥ 40 mL/min,&#xD;
&#xD;
         10. Adequate coagulation parameters, defined as International Normalisation Ratio &lt;1.5 x&#xD;
             ULN or activated partial thromboplastin time &lt;1.5 x ULN.&#xD;
&#xD;
         11. Patients with known tumor thrombus or deep vein thrombosis are eligible if stable on&#xD;
             low molecular weight heparin for ≥4 weeks.&#xD;
&#xD;
         12. Females should be using adequate contraceptive measures should not be breast feeding,&#xD;
             and must have a negative pregnancy test prior to start of dosing if of childbearing&#xD;
             potential or must have evidence of non-childbearing potential&#xD;
&#xD;
         13. Male patients should be willing to use barrier contraception, i.e. condoms.&#xD;
&#xD;
         14. Ability to swallow and retain oral medications.&#xD;
&#xD;
         15. Predicted life expectancy ≥12 weeks.&#xD;
&#xD;
         16. Aged at least 18 years.&#xD;
&#xD;
         17. Willingness and ability to comply with study and follow-up procedures.&#xD;
&#xD;
         18. Ability to understand the nature of this study and give written informed consent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational&#xD;
             agents &lt;21 days of the first dose of study treatment. Most recent targeted therapy &lt;14&#xD;
             days of the first dose of study treatment.&#xD;
&#xD;
          2. Unresolved toxicities from any prior therapy greater than Common Terminology Criteria&#xD;
             for Adverse Events Grade 1 at the time of starting study treatment with the exception&#xD;
             of alopecia.&#xD;
&#xD;
          3. Prior or current treatment with a cMet inhibitor&#xD;
&#xD;
          4. Strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4), strong inhibitors of&#xD;
             cytochrome P450 1A2 (CYP1A2), or CYP3A4 substrates with a narrow therapeutic range&#xD;
             within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)&#xD;
&#xD;
          5. Wide field radiotherapy (including therapeutic radioisotopes such as strontium-89)&#xD;
             administered ≤28 days or limited field radiation for palliation ≤7 days prior to&#xD;
             starting study drug or has not recovered from side effects of such therapy&#xD;
&#xD;
          6. Major surgical procedures ≤28 days of beginning study drug or minor surgical&#xD;
             procedures ≤7 days. No waiting is required following port-a-cath placement.&#xD;
&#xD;
          7. Previously untreated brain metastases.&#xD;
&#xD;
          8. Current leptomeningeal metastases or spinal cord compression due to disease.&#xD;
&#xD;
          9. Acute or chronic liver or pancreatic disease.&#xD;
&#xD;
         10. Uncontrolled diabetes mellitus.&#xD;
&#xD;
         11. Gastrointestinal disease or other condition that will interfere significantly with the&#xD;
             absorption, distribution, metabolism, or excretion of oral therapy&#xD;
&#xD;
         12. Any of the following cardiac diseases currently or within the last 6 months:&#xD;
&#xD;
               1. Unstable angina pectoris&#xD;
&#xD;
               2. Congestive heart failure (New York Heart Association ≥ Grade 2)&#xD;
&#xD;
               3. Acute myocardial infarction&#xD;
&#xD;
               4. Stroke or transient ischemic attack&#xD;
&#xD;
         13. Inadequately controlled hypertension (i.e., systolic blood pressure &gt;160 mmHg or&#xD;
             diastolic blood pressure &gt;100 mmHg) (patients with values above these levels must have&#xD;
             their blood pressure controlled with medication prior to starting treatment).&#xD;
&#xD;
         14. Mean resting correct QT interval (QTc) &gt;470 msec obtained from triplicate&#xD;
             electrocardiagrams&#xD;
&#xD;
         15. Any clinically important abnormalities in rhythm, conduction or morphology of resting&#xD;
             electrocardiograms, e.g. complete left bundle branch block, third degree heart block,&#xD;
             second degree heart block, PR interval &gt;250 msec.&#xD;
&#xD;
         16. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events&#xD;
             such as heart failure, hypokalaemia, congenital or familial long QT syndrome or family&#xD;
             history of unexplained sudden death under 40 years of age or any concomitant&#xD;
             medications known to prolong QT interval.&#xD;
&#xD;
         17. Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular&#xD;
             weight heparin is allowed.&#xD;
&#xD;
         18. Serious active infection at the time of treatment, or another serious underlying&#xD;
             medical condition that would impair the ability of the patient to receive protocol&#xD;
             treatment.&#xD;
&#xD;
         19. Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.&#xD;
&#xD;
         20. Presence of other active cancers, or history of treatment for invasive cancer ≤5years.&#xD;
             Patients with Stage I cancer who have received definitive local treatment at least 3&#xD;
             years previously, and are considered unlikely to recur are eligible. All patients with&#xD;
             previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are&#xD;
             patients with history of non-melanoma skin cancer.&#xD;
&#xD;
         21. Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik-Tobias Arkenau, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sarah Cannon Research Institute United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2609&amp;filename=d5082c00002-revised-csp-3_Redacted.pdf</url>
    <description>D5082c00002-revised-csp-3_Redacted</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <results_first_submitted>September 13, 2017</results_first_submitted>
  <results_first_submitted_qc>September 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2017</results_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD6094</keyword>
  <keyword>Savolitinib</keyword>
  <keyword>Papillary Renal Cell Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>111 patients were enrolled; 109 patients received at least one dose of AZD6094 administered orally (po). Two patients withdrew prior to receiving any study drug. The study was conducted at 23 international sites in the United States, Canada, United Kingdom and Spain.</recruitment_details>
      <pre_assignment_details>All patients were required to provide an archived or fresh tumour sample at enrolment to confirm eligibility, and for performance of the c-MET biomarker analysis. c-MET biomarker results determined the subgroup placement for data analysis as follows: c-MET positive (n=46), c-MET negative (n=47), and c-MET unknown (n=16).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>c-MET Positive [600mg AZD6094 po]</title>
          <description>All participants tested for the presence of c-MET mutations</description>
        </group>
        <group group_id="P2">
          <title>c-MET Negative [600mg AZD6094 po]</title>
          <description>All participants were tested for the presence of c-MET mutations.</description>
        </group>
        <group group_id="P3">
          <title>c-MET Status Unknown [600mg AZD6094 po]</title>
          <description>All participants were tested for the presence of c-MET mutations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who received at least one dose of AZD6094 are included in the baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>c-MET Positive [600mg AZD6094 po]</title>
          <description>All participants tested for the presence of c-MET mutations</description>
        </group>
        <group group_id="B2">
          <title>c-MET Negative [600mg AZD6094 po]</title>
          <description>All participants were tested for the presence of c-MET mutations.</description>
        </group>
        <group group_id="B3">
          <title>c-MET Status Unknown [600mg AZD6094 po]</title>
          <description>All participants were tested for the presence of c-MET mutations.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="23" upper_limit="87"/>
                    <measurement group_id="B2" value="64" lower_limit="29" upper_limit="75"/>
                    <measurement group_id="B3" value="61" lower_limit="37" upper_limit="80"/>
                    <measurement group_id="B4" value="64" lower_limit="23" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>ECOG Performance Status (PS): (0) = Fully active; (1) Restricted in physically strenuous activity; (2) Ambulatory and capable of self-care; (3) Capable of limited self-care; (4) Completely disabled</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>PS=0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS=1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS=2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS=3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS=4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PRCC Confirmation from Central Laboratory</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>PRCC Not Confirmed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PRCC Confirmed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Low</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intermediate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Cell Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Type I PRCC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type II PRCC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unclassified PRCC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MSKCC Risk Group</title>
          <description>Risk categories for patients were obtained from the Memorial Sloan Kettering Cancer Center (MSKCC) risk category prognostic model in advanced renal cell cancer, as follows: Favourable risk = 0 risk factors; Intermediate risk = 10 or 2 risk factors; Poor risk = 3 or more risk factors. Risk factors include: Karnofsky performance status &lt; 80%; time from diagnosis to salvage treatment &lt; 1 year; haemoglobin &lt; lower limit of normal (LLN); corrected serum calcium &gt; ULN; and serum lactate dehydrogenase &gt; 1.5 x ULN.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Favourable Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intermediate Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.42" spread="20.74"/>
                    <measurement group_id="B2" value="85.38" spread="23.84"/>
                    <measurement group_id="B3" value="84.90" spread="12.55"/>
                    <measurement group_id="B4" value="82.37" spread="21.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" lower_limit="42" upper_limit="134"/>
                    <measurement group_id="B2" value="83.5" lower_limit="47" upper_limit="160.6"/>
                    <measurement group_id="B3" value="87.65" lower_limit="59.3" upper_limit="101.6"/>
                    <measurement group_id="B4" value="79.5" lower_limit="42" upper_limit="160.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (RECIST Version 1.1)</title>
        <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to Response Evaluation Criteria for Solid Tumours (RECIST) v1.1.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>ORR was assessed on the efficacy analysis set, consisting of all patients with measurable disease, PRCC confirmed by a central laboratory and have received at least 1 dose of AZD6094 (n = 85).</population>
        <group_list>
          <group group_id="O1">
            <title>Efficacy Analysis Set</title>
            <description>All patients with measurable disease, PRCC confirmed by central laboratory and received at least 1 dose of study medication</description>
          </group>
          <group group_id="O2">
            <title>Safety Analysis Set</title>
            <description>All patients who have received at least 1 dose of study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (RECIST Version 1.1)</title>
          <description>The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to Response Evaluation Criteria for Solid Tumours (RECIST) v1.1.</description>
          <population>ORR was assessed on the efficacy analysis set, consisting of all patients with measurable disease, PRCC confirmed by a central laboratory and have received at least 1 dose of AZD6094 (n = 85).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease &gt;= 5 Weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set</title>
        <description>The primary outcome measure was ORR, defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
        <time_frame>12 Months</time_frame>
        <population>ORR was assessed on the efficacy analysis set, consisting of all patients with measurable disease, PRCC confirmed by a central laboratory and received at least 1 dose of AZD6094 (n = 85).</population>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O4">
            <title>Total [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set</title>
          <description>The primary outcome measure was ORR, defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.</description>
          <population>ORR was assessed on the efficacy analysis set, consisting of all patients with measurable disease, PRCC confirmed by a central laboratory and received at least 1 dose of AZD6094 (n = 85).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease &gt;= 5 weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set</title>
        <description>The primary outcome measure was ORR, defined as the proportion of patients with either a confirmed complete response/partial response by investigator assessment according to RECIST v1.1.</description>
        <time_frame>12 Months</time_frame>
        <population>ORR was assessed on the safety analysis set, consisting of all patients who received at least one dose of the study drug (n = 109).</population>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O4">
            <title>Total [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set</title>
          <description>The primary outcome measure was ORR, defined as the proportion of patients with either a confirmed complete response/partial response by investigator assessment according to RECIST v1.1.</description>
          <population>ORR was assessed on the safety analysis set, consisting of all patients who received at least one dose of the study drug (n = 109).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease &gt;= 5 weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival Stratified by c-MET Status in the Efficacy Analysis Set</title>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Stratified by c-MET Status in the Efficacy Analysis Set</title>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="12.3" upper_limit="35.4"/>
                    <measurement group_id="O2" value="9.7" lower_limit="6.1" upper_limit="12.4"/>
                    <measurement group_id="O3" value="6.1" lower_limit="5.1" upper_limit="NA">Due to insufficient number of events, the upper limit of the 95% CI for median PFS was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Stratified by c-MET Status in the Efficacy Analysis Set</title>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Stratified by c-MET Status in the Efficacy Analysis Set</title>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="34.6" upper_limit="NA">As the sufficient number of events was not reached at the time of data cut-off, the median OS and the upper limit of the 95% CI for median OS were not calculable.</measurement>
                    <measurement group_id="O2" value="61.1" lower_limit="29.4" upper_limit="NA">Due to insufficient number of events, the upper limit of the 95% CI for median OS was not calculable.</measurement>
                    <measurement group_id="O3" value="51.5" lower_limit="8.1" upper_limit="NA">Due to insufficient number of events, the upper limit of the 95% CI for median OS was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival Stratified by c-MET Status in the Safety Analysis Set</title>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Stratified by c-MET Status in the Safety Analysis Set</title>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="17.7" upper_limit="35.4"/>
                    <measurement group_id="O2" value="6.6" lower_limit="6.1" upper_limit="11.9"/>
                    <measurement group_id="O3" value="12.1" lower_limit="6.1" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Stratified by c-MET Status in the Safety Analysis Set</title>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Stratified by c-MET Status in the Safety Analysis Set</title>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="42.9" upper_limit="NA">As the sufficient number of events was not reached at the time of data cut-off, the median OS and the upper limit of the 95% CI for median OS were not calculable.</measurement>
                    <measurement group_id="O2" value="61.1" lower_limit="40.6" upper_limit="106.7"/>
                    <measurement group_id="O3" value="54.9" lower_limit="18.4" upper_limit="NA">Due to insufficient number of events, the upper limit of the 95% CI for median OS was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Efficacy Analysis Set</title>
        <description>12 week summary for patients in the Efficacy analysis set, by MET status. The numbers of patients analysed represent the numbers evaluable at the 12 week timepoint.</description>
        <time_frame>12 Weeks (at 12 weeks timepoint)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Efficacy Analysis Set</title>
          <description>12 week summary for patients in the Efficacy analysis set, by MET status. The numbers of patients analysed represent the numbers evaluable at the 12 week timepoint.</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="21.56"/>
                    <measurement group_id="O2" value="3.4" spread="20.05"/>
                    <measurement group_id="O3" value="7.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Safety Analysis Set.</title>
        <description>12 week summary for patients in the Safety analysis set by MET Status. The number of patients analysed represent the number of evaluable patients at the 12 week timepoint.</description>
        <time_frame>12 Weeks (at 12 week timepoint)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>c-MET Positive [600mg AZD6094 po]</title>
            <description>All participants tested for the presence of c-MET mutations</description>
          </group>
          <group group_id="O2">
            <title>c-MET Negative [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
          <group group_id="O3">
            <title>c-MET Status Unknown [600mg AZD6094 po]</title>
            <description>All participants were tested for the presence of c-MET mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Safety Analysis Set.</title>
          <description>12 week summary for patients in the Safety analysis set by MET Status. The number of patients analysed represent the number of evaluable patients at the 12 week timepoint.</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="21.39"/>
                    <measurement group_id="O2" value="4.3" spread="18.96"/>
                    <measurement group_id="O3" value="5.1" spread="17.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of Response is the time from the first documentation of confirmed complete response/partial response until the date of progression, or death in the absence of progression. There were 8 responders: one of whom subsequently progressed or died and seven of whom were still classified as responders at the time of data cut-off and were therefore censored. It was not possible to determine a median or 75th percentile.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set [600mg AZD6094 po]</title>
            <description>All patients who have received at least 1 dose of study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of Response is the time from the first documentation of confirmed complete response/partial response until the date of progression, or death in the absence of progression. There were 8 responders: one of whom subsequently progressed or died and seven of whom were still classified as responders at the time of data cut-off and were therefore censored. It was not possible to determine a median or 75th percentile.</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="18.1" upper_limit="NA">The median DoR and 75th percentile for DoR were not calculable within the timeframe of this study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration of AZD6094 Following Single Dose</title>
        <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Set [600mg AZD6094 po]</title>
            <description>All patients that received at least one dose of study medication and had evaluable PK data</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration of AZD6094 Following Single Dose</title>
          <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3038.8984" spread="44.4184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Plasma Concentration of AZD6094 After Single Dose</title>
        <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Set [600mg AZD6094 po]</title>
            <description>All patients that received at least one dose of study medication and had evaluable PK data</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Plasma Concentration of AZD6094 After Single Dose</title>
          <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution of AZD6094 Following Single Dose</title>
        <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Set [600mg AZD6094 po]</title>
            <description>All patients that received at least one dose of study medication and had evaluable PK data</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution of AZD6094 Following Single Dose</title>
          <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.4237" spread="36.5971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose</title>
        <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Set [600mg AZD6094 po]</title>
            <description>All patients that received at least one dose of study medication and had evaluable PK data</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose</title>
          <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13144.7381" spread="36.4328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose (Time Zero to Last Measurement)</title>
        <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Set [600mg AZD6094 po]</title>
            <description>All patients that received at least one dose of study medication and had evaluable PK data</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose (Time Zero to Last Measurement)</title>
          <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13214.2441" spread="46.4616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Clearance of AZD6094 From Plasma After Single Dose</title>
        <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Set [600mg AZD6094 po]</title>
            <description>All patients that received at least one dose of study medication and had evaluable PK data</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Clearance of AZD6094 From Plasma After Single Dose</title>
          <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
          <units>L/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4938" spread="17.3386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time of AZD6094 After Single Dose</title>
        <description>The number of patients analysed represent the number of evaluable PK parameters for this endpoint.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Set [600mg AZD6094 po]</title>
            <description>All patients that received at least one dose of study medication and had evaluable PK data</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time of AZD6094 After Single Dose</title>
          <description>The number of patients analysed represent the number of evaluable PK parameters for this endpoint.</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9837" spread="0.4813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-Life of AZD6094 After Single Dose</title>
        <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacokinetic Analysis Set [600mg AZD6094 po]</title>
            <description>All patients that received at least one dose of study medication and had evaluable PK data</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-Life of AZD6094 After Single Dose</title>
          <description>The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0499" spread="0.3820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZD6094 600 mg Per Day Orally</title>
          <description>All patients who received at least one dose of study medication</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Myocardial Infaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Drug-induced Liver Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Peripheral oedema</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Blood alklaine phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arthalgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For the secondary outcome measure Duration of Response the median was not calculable because at data cut-off some participants were still responding.&#xD;
Point to note: All patients on this trial received 600mg AZD6094 po.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Medical Director, Savolitinib</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

